X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (7014) 7014
Publication (1484) 1484
Book Review (99) 99
Book Chapter (60) 60
Conference Proceeding (16) 16
Book / eBook (5) 5
Dissertation (4) 4
Reference (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4974) 4974
index medicus (4938) 4938
animals (3230) 3230
biochemistry & molecular biology (1623) 1623
histone deacetylase inhibitors (1600) 1600
mice (1552) 1552
cancer (1511) 1511
oncology (1454) 1454
histone deacetylase (1439) 1439
cell biology (1385) 1385
cell line, tumor (1310) 1310
acetylation (1309) 1309
histones - metabolism (1247) 1247
histone deacetylases - metabolism (1222) 1222
gene expression (1202) 1202
histone deacetylase inhibitors - pharmacology (1187) 1187
apoptosis (1093) 1093
epigenetics (1081) 1081
dna methylation (1069) 1069
article (1032) 1032
male (1022) 1022
female (959) 959
expression (931) 931
proteins (922) 922
gene-expression (910) 910
chromatin (908) 908
research (908) 908
methylation (838) 838
hydroxamic acids - pharmacology (823) 823
enzyme inhibitors - pharmacology (779) 779
pharmacology & pharmacy (731) 731
histones (686) 686
antineoplastic agents - pharmacology (675) 675
apoptosis - drug effects (674) 674
analysis (666) 666
genetic aspects (661) 661
transcription (651) 651
histone deacetylase inhibitor (638) 638
epigenesis, genetic (606) 606
signal transduction (604) 604
health aspects (593) 593
epigenetic inheritance (564) 564
activation (560) 560
cells, cultured (560) 560
cell line (557) 557
cell proliferation - drug effects (530) 530
physiological aspects (526) 526
genes (503) 503
phosphorylation (494) 494
care and treatment (488) 488
neurosciences (484) 484
promoter regions, genetic (484) 484
repressor proteins - metabolism (473) 473
rats (463) 463
multidisciplinary sciences (459) 459
histone deacetylases - genetics (449) 449
protein binding (444) 444
research article (439) 439
genetics & heredity (438) 438
in-vivo (433) 433
cells (430) 430
transcription factors - metabolism (420) 420
signal transduction - drug effects (412) 412
chemistry, medicinal (410) 410
kinases (401) 401
nf-kappa-b (395) 395
antineoplastic agents - therapeutic use (390) 390
enzymes (389) 389
medicine (386) 386
differentiation (381) 381
biology (374) 374
inhibitors (373) 373
hematology (365) 365
cell cycle (363) 363
valproic acid (355) 355
histone deacetylase inhibitors - therapeutic use (353) 353
transcription, genetic (352) 352
in-vitro (349) 349
mutation (348) 348
protein (347) 347
dose-response relationship, drug (342) 342
transcription factors (342) 342
tumors (342) 342
acetylation - drug effects (339) 339
dna (334) 334
down-regulation (334) 334
blotting, western (331) 331
gene expression regulation (331) 331
histone deacetylases (331) 331
rna interference (330) 330
neoplasms - drug therapy (329) 329
histone acetylation (328) 328
deoxyribonucleic acid--dna (324) 324
cell proliferation (323) 323
mice, inbred c57bl (322) 322
inhibition (319) 319
gene expression regulation, neoplastic (318) 318
gene expression regulation, neoplastic - drug effects (314) 314
gene (310) 310
endocrinology & metabolism (309) 309
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Neuroscience, ISSN 1097-6256, 09/2012, Volume 15, Issue 9, pp. 1245 - 1254
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 03/2011, Volume 406, Issue 2, pp. 292 - 298
► Nrf2 anti-oxidant function is impaired when HDAC activity is inhibited. ► HDAC inhibition decreases Nrf2 protein stability. ► HDAC2 is involved in reduced... 
Oxidative stress | Protein stability | Histone deacetylase 2 | Acetylation | Nrf2 | COPD | SMOKE-INDUCED EMPHYSEMA | PROTEASOMAL DEGRADATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | IDENTIFICATION | OLIGONUCLEOTIDE MICROARRAY | OBSTRUCTIVE PULMONARY-DISEASE | TRANSCRIPTION FACTOR NRF2 | GLUCOCORTICOID-RECEPTOR | BIOPHYSICS | SIGNALING PATHWAY | GENE-EXPRESSION | ANTIOXIDANT RESPONSE | Cell Line | Histone Deacetylase 2 - genetics | NF-E2-Related Factor 2 - antagonists & inhibitors | Histone Deacetylase 2 - antagonists & inhibitors | Humans | Mice, Inbred C57BL | Gene Expression Regulation | Hydrogen Peroxide - pharmacology | Oxidative Stress - genetics | Male | Smoke | Gene Knockdown Techniques | Smoking - metabolism | Animals | NF-E2-Related Factor 2 - metabolism | Mice | Histone Deacetylase 2 - metabolism | Protein Stability | Pulmonary Disease, Chronic Obstructive - metabolism | Pulmonary Disease, Chronic Obstructive - genetics | Lung diseases, Obstructive | Hydrogen peroxide | Parkinson's disease | Acetates | Heme | OXIDATION | RNA | ACETYLATION | MACROPHAGES | MONOCYTES | IN VIVO | 60 APPLIED LIFE SCIENCES | ECR HEATING | NERVOUS SYSTEM DISEASES | TOBACCO SMOKES | INHIBITION | HEME | HYDROGEN PEROXIDE | OXIDIZERS | GENES | MICE | PROTEINS | ARE, anti oxidant response element | COPD, chronic obstructive pulmonary disease | Nrf2, nuclear factor erythroid 2-related factor 2 | MDM, monocyte-derived macrophage | H2O2, hydrogen peroxide | DJ-1, Parkinson’s disease (PD)-associated protein | HDAC2, histone deacetylase-2 | ROS, reactive oxygen species | Keap1, Kelch-like ECH associated protein 1 | HO-1, heme oxygenase-1 | TSA, trichostatin A
Journal Article
PLoS ONE, ISSN 1932-6203, 08/2013, Volume 8, Issue 8, p. e71323
Psychiatric diseases, including schizophrenia, bipolar disorder and major depression, are projected to lead global disease burden within the next decade.... 
HIPPOCAMPUS | MESSENGER-RNA | ACETYLATION | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | STRAIN DIFFERENCES | VALPROIC ACID | MICE | HISTONE DEACETYLASE INHIBITORS | LITHIUM | NUCLEUS-ACCUMBENS | Transcription, Genetic - drug effects | Male | Neurons - cytology | Promoter Regions, Genetic - drug effects | Promoter Regions, Genetic - genetics | Brain - metabolism | Mi-2 Nucleosome Remodeling and Deacetylase Complex - antagonists & inhibitors | Time Factors | Behavior, Animal - drug effects | Histone Deacetylase 1 - antagonists & inhibitors | Benzamides - pharmacology | Neurons - drug effects | Chromatin - drug effects | Benzamides - chemistry | Affect - drug effects | Brain - cytology | Reproducibility of Results | Histone Deacetylase 2 - antagonists & inhibitors | Lithium - pharmacology | Mice, Inbred C57BL | Histone Deacetylase Inhibitors - chemistry | Brain - drug effects | Gene Expression Regulation - drug effects | Acetylation - drug effects | Animals | Histone Deacetylase Inhibitors - pharmacology | Mice | Histones - metabolism | Chromatin - genetics | Epigenetic inheritance | Brain | Chromatin | Antidepressants | Genes | Depression, Mental | Schizophrenia | Gene expression | Drugs | Drug abuse | Histone deacetylase | Immunoprecipitation | Transcription | Mental disorders | Medical services | Disorders | Lithium | Bipolar disorder | Genomes | Mental depression | Compounds | Kinases | Benzamide | Psychotropic drugs | Plasticity (behavioral) | Rodents | Inhibition | Acetylation | HDAC2 protein | Locomotor activity | Binding | Cortex (prefrontal) | Hydroxamic acid | Pharmacology | Nucleus accumbens | Amphetamine | Mood | Inhibitors | Acids | In vivo methods and tests
Journal Article
Journal Article
Oncogene, ISSN 0950-9232, 02/2012, Volume 31, Issue 5, pp. 537 - 551
The class-I histone deacetylases (HDACs) HDAC1 and HDAC2 belong to a family of 11 zinc-dependent human HDACs and are overexpressed in many cancers. Inhibitors... 
apoptosis | cancer | sphingosine-1-phosphate | histone deacetylase | histone deacetylase inhibitor | MULTIPLE-MYELOMA | HDAC INHIBITORS | DIFFERENTIAL EXPRESSION | HUMAN LEUKEMIA-CELLS | SUBEROYLANILIDE HYDROXAMIC ACID | REVERSIBLE ACETYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | DNA-DAMAGE | SYNERGISTICALLY INDUCES APOPTOSIS | MEDIATED PHOSPHORYLATION | CELL BIOLOGY | ONCOLOGY | GENETICS & HEREDITY | NF-KAPPA-B | Neoplasms - metabolism | Lysophospholipids - metabolism | Histone Deacetylase 2 - antagonists & inhibitors | Humans | Neoplasms - enzymology | Depsipeptides - pharmacology | Neoplasms - drug therapy | Sphingosine - analogs & derivatives | Models, Biological | Histone Deacetylase 1 - antagonists & inhibitors | Histone Deacetylase Inhibitors - pharmacology | Hydroxamic Acids - therapeutic use | Depsipeptides - therapeutic use | Histone Deacetylase Inhibitors - therapeutic use | Sphingosine - metabolism | Histone Deacetylase 2 - metabolism | Hydroxamic Acids - pharmacology | Histone Deacetylase 1 - metabolism | Antimitotic agents | Care and treatment | Sphingosine | Histones | Physiological aspects | Development and progression | Drug targeting | Antineoplastic agents | Health aspects | Cancer | Clinical trials | Molecules | Pharmacology | Gene expression | Cancer therapies | Enzymes | Histone deacetylase | Sphingolipids | Nuclei | epigenetics | Chromatin remodeling | Antitumor agents | Molecular modelling | Reviews | Lipid metabolism | HDAC2 protein
Journal Article
Journal Article
Journal of Molecular and Cellular Cardiology, ISSN 0022-2828, 2014, Volume 72, pp. 138 - 145
Abstract While inhibition of class I/IIb histone deacetylases (HDACs) protects the mammalian heart from ischemia reperfusion (IR) injury, class selective... 
Cardiovascular | Histone deacetylase | FOXO | Superoxide dismutase | Isolated heart | Catalase | Ischemia reperfusion | HDAC INHIBITORS | CARDIAC & CARDIOVASCULAR SYSTEMS | ACETYLATION | INJURY | FOXO TRANSCRIPTION FACTORS | HYPOXIA | CELL BIOLOGY | SUPEROXIDE-DISMUTASE | Superoxide Dismutase - genetics | Myocardial Contraction - drug effects | Male | Myocardial Reperfusion Injury - enzymology | Forkhead Transcription Factors - metabolism | Histone Deacetylase 1 - antagonists & inhibitors | Indoles - pharmacology | Benzamides - pharmacology | Histone Deacetylase 1 - genetics | Hydroxamic Acids - pharmacology | Myocardial Reperfusion Injury - genetics | Organ Culture Techniques | Superoxide Dismutase - metabolism | Heart - physiopathology | Histone Deacetylase 2 - genetics | Histone Deacetylases - genetics | Catalase - genetics | Histone Deacetylase 2 - antagonists & inhibitors | Histone Deacetylase 6 | Gene Expression Regulation | Rats | Histone Deacetylases - metabolism | Forkhead Transcription Factors - genetics | Rats, Sprague-Dawley | Myocardial Reperfusion Injury - physiopathology | Catalase - metabolism | Animals | Heart - drug effects | Histone Deacetylase Inhibitors - pharmacology | Pyridines - pharmacology | Histone Deacetylase 2 - metabolism | Forkhead Box Protein O3 | Myocardial Reperfusion Injury - prevention & control | Histone Deacetylase 1 - metabolism | Antioxidants | Ischemia | Superoxide | ischemia reperfusion | isolated heart | histone deacetylase | superoxide dismutase | catalase
Journal Article
Diabetes, ISSN 0012-1797, 03/2013, Volume 62, Issue 3, pp. 732 - 742
Chromatin modifications are sensitive to environmental and nutritional stimuli. Abnormalities in epigenetic regulation are associated with metabolic disorders... 
COMPLEX | EPIGENETICS | MECHANISM | PHOSPHORYLATION | BROWN ADIPOCYTES | ENDOCRINOLOGY & METABOLISM | BUTYRATE | DIFFERENTIATION | PPAR-GAMMA ACTIVATION | INSULIN SENSITIVITY | EXPRESSION | Obesity - drug therapy | Mitochondria, Muscle - metabolism | Adipose Tissue - cytology | Male | Muscle, Skeletal - metabolism | Diabetes Mellitus, Type 2 - metabolism | Molecular Targeted Therapy | Anti-Obesity Agents - therapeutic use | Adipose Tissue - metabolism | Mice, Mutant Strains | Muscle, Skeletal - drug effects | Histone Deacetylase 1 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Cell Line | Histone Deacetylase 2 - antagonists & inhibitors | Obesity - complications | Cells, Cultured | Muscle, Skeletal - ultrastructure | Random Allocation | Hypoglycemic Agents - pharmacology | Obesity - metabolism | Obesity - pathology | Gene Expression Regulation - drug effects | Animals | Adipose Tissue - ultrastructure | Histone Deacetylase Inhibitors - pharmacology | Mitochondria, Muscle - ultrastructure | Histone Deacetylase Inhibitors - therapeutic use | Mice | Mitochondria, Muscle - drug effects | Diabetes Mellitus, Type 2 - pathology | Histone Deacetylase 2 - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Adipose Tissue - drug effects | Anti-Obesity Agents - pharmacology | Energy Metabolism - drug effects | Histone Deacetylase 1 - metabolism | Type 2 diabetes | Care and treatment | Enzyme inhibitors | Histones | Cell metabolism | Muscles | Physiological aspects | Research | Acetylation | Metabolism
Journal Article